Abstract
Metabolic syndrome is a disorder of energy consumption and storage. The use of atypical antipsychotics were reported to cause the metabolic disorders which occurs in medical circumstances like abnormal findings include insulin resistance, elevated fasting plasma glucose, triglyceride levels (TG), cholesterol levels (TC) and BMI. Our aim was to assess the metabolic disorders associated with atypical antipsychotics. A Prospective Observational Study (follw-up study) was carried out in Psychiatric department of Rajiv Gandhi Institute of Medical Science, Kadapa for a period of 6 months. The patient’s base-line values of blood glucose, lipid profiles (TG, TC) and BMI were recorded and regular follow-ups were done for every 4 weeks until 3 months and finally the metabolic disorders associated with atypical antipsychotics were assessed. Finally in framing results we have recruited 23 patients out of 180 and incidence rate of 0.12. The baseline values were normal and at end of the study their values were for the particular metabolic disorder and shows that BMI (50.43%) tends to vary most next weight (48.64%) and FBS (42.48%) varies with the use of atypical antipsychotics.The drugs tends to cause metabolic disorders fall in the order, OLANZAPINE (10mg) > CLOZAPINE (10mg) + RISPERIDONE (3mg) > RISPERIDONE (3mg) > OLANZAPINE (5mg) > OLANZAPINE (10mg) + CLOZAPINE (50mg) > RISPERIDONE (2mg). AAPs are producing an increased incidence of metabolic diseases (blood glucose, TC, TG, weight gain) so the management of psychiatric disorders should be multidisciplinary including psychiatrist, diabetologist and paramedical staff.
